RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 12, Leonid Timashev from RBC Capital reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a price target of $77.00.

Legend Biotech Corporation (NASDAQ:LEGN) reported CARVYKTI net trade sales of around $439 million in fiscal Q2 2025, with CARVYKTI demonstrating “positive long-term outcomes in the CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years.”

Management also reported cash and cash equivalents, and time deposits of $1.0 billion as of June 30.

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.

While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.